Literature DB >> 8616634

Editing for an AMPA receptor subunit RNA in prefrontal cortex and striatum in Alzheimer's disease, Huntington's disease and schizophrenia.

S Akbarian1, M A Smith, E G Jones.   

Abstract

Animal studies and cell culture experiments demonstrated that posttranscriptional editing of the transcript of the GluR-2 gene, resulting in substitution of an arginine for glutamine in the second transmembrane region (TM II) of the expressed protein, is associated with a reduction in Ca2+ permeability of the receptor channel. Thus, disturbances in GluR-2 RNA editing with alteration of intracellular Ca2+ homeostasis could lead to neuronal dysfunction and even neuronal degeneration. The present study determined the proportions of edited and unedited GluR-2 RNA in the prefrontal cortex of brains from patients with Alzheimer's disease, in the striatum of brains from patients with Huntington's disease, and in the same areas of brains from age-matched schizophrenics and controls, by using reverse transcriptase-polymerase chain reaction, restriction endonuclease digestion, gel electrophoresis and scintillation radiometry. In the prefrontal cortex of controls, < 0.1% of all GluR-2 RNA molecules were unedited and > 99.9% were edited; in the prefrontal cortex both of schizophrenics and of Alzheimer's patients approximately 1.0% of all GluR-2 RNA molecules were unedited and 99% were edited. In the striatum of controls and of schizophrenics, approximately 0.5% of GluR-2 RNA molecules were unedited and 99.5% were edited; in the striatum of Huntington's patients nearly 5.0% of GluR-2 RNA was unedited. In the prefrontal white matter of controls, approximately 7.0% of GluR-2 RNA was unedited. In the normal human prefrontal cortex and striatum, the large majority of GluR-2 RNA molecules contains a CGG codon for arginine in the TMII coding region; this implies that the corresponding AMPA receptors have a low Ca2+ permeability, as previously demonstrated for the rat brain. The process of GluR-2 RNA editing is compromised in a region-specific manner in schizophrenia, in Alzheimer's disease and Huntington's Chorea although in each of these disorders there is still a large excess of edited GluR-2 RNA molecules. Disturbances of GluR-2 RNA editing leading to excessive Ca2+ permeability, may contribute to neuronal dysfunction in schizophrenia and to neuronal death in Alzheimer's disease and Huntington's disease.

Entities:  

Keywords:  NASA Discipline Neuroscience; Non-NASA Center

Mesh:

Substances:

Year:  1995        PMID: 8616634     DOI: 10.1016/0006-8993(95)00922-d

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  45 in total

Review 1.  Adenosine deaminases acting on RNA, RNA editing, and interferon action.

Authors:  Cyril X George; Zhenji Gan; Yong Liu; Charles E Samuel
Journal:  J Interferon Cytokine Res       Date:  2010-12-23       Impact factor: 2.607

2.  An accurate fluorescent assay for quantifying the extent of RNA editing.

Authors:  Loretta M Roberson; Joshua J C Rosenthal
Journal:  RNA       Date:  2006-09-06       Impact factor: 4.942

3.  Spontaneous metastasis in mouse models of testicular germ-cell tumours.

Authors:  J L Zechel; G T MacLennan; J D Heaney; J H Nadeau
Journal:  Int J Androl       Date:  2011-06-09

Review 4.  Novel RNA modifications in the nervous system: form and function.

Authors:  John S Satterlee; Maria Basanta-Sanchez; Sandra Blanco; Jin Billy Li; Kate Meyer; Jonathan Pollock; Ghazaleh Sadri-Vakili; Agnieszka Rybak-Wolf
Journal:  J Neurosci       Date:  2014-11-12       Impact factor: 6.167

5.  Chronic glutamate treatment selectively modulates AMPA RNA editing and ADAR expression and activity in primary cortical neurons.

Authors:  Daniela Bonini; Alice Filippini; Luca La Via; Chiara Fiorentini; Fabio Fumagalli; Marina Colombi; Alessandro Barbon
Journal:  RNA Biol       Date:  2015       Impact factor: 4.652

6.  Pharmacological characterization of N-[(2S)-5-(6-fluoro-3-pyridinyl)-2, 3-dihydro-1H-inden-2-yl]-2-propanesulfonamide: a novel, clinical AMPA receptor positive allosteric modulator.

Authors:  Simon E Ward; Paul Beswick; Novella Calcinaghi; Lee A Dawson; Jane Gartlon; Francesca Graziani; Declan N C Jones; Laurent Lacroix; M H Selina Mok; Beatrice Oliosi; Joanne Pardoe; Kathryn Starr; Marie L Woolley; Mark H Harries
Journal:  Br J Pharmacol       Date:  2017-01-31       Impact factor: 8.739

Review 7.  Pharmacology of AMPA/kainate receptor ligands and their therapeutic potential in neurological and psychiatric disorders.

Authors:  G J Lees
Journal:  Drugs       Date:  2000-01       Impact factor: 9.546

8.  SRRM2, a potential blood biomarker revealing high alternative splicing in Parkinson's disease.

Authors:  Lina A Shehadeh; Kristine Yu; Liyong Wang; Alexandra Guevara; Carlos Singer; Jeffery Vance; Spyridon Papapetropoulos
Journal:  PLoS One       Date:  2010-02-08       Impact factor: 3.240

9.  Dysregulated A to I RNA editing and non-coding RNAs in neurodegeneration.

Authors:  Minati Singh
Journal:  Front Genet       Date:  2013-01-22       Impact factor: 4.599

10.  Glutamate Neurotransmission in Psychotic Disorders and Substance Abuse.

Authors:  Berit Kerner
Journal:  Open Psychiatr J       Date:  2009-01-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.